Corporate / CVC
Every published round Boehringer Ingelheim took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Boehringer Ingelheim has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Boehringer Ingelheim, as distinct from the investments it has made.
Companies Boehringer Ingelheim has backed that another company then bought. An exit for the holding, not a deal Boehringer Ingelheim did.
Stories naming Boehringer Ingelheim. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian startups raised funds including Alloy Robotics, Farmbot and Atmo Biosciences. Firmus Technologies acquired Benmax while Tabcorp bought BetMakers. SafetyCulture rebranded to Mitti.
Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
University of Sydney spinout Kinoxis Therapeutics signs a licensing and partnership deal with Boehringer Ingelheim to develop psychiatric treatments, with payments and R&D support worth up to $266 million.
Sydney clinical trials platform HealthMatch raised a $10 million Series C led by Folklore Ventures with Square Peg participating, after laying off half its staff in June; funds will support rehiring and US expansion.
Also SmartCompany·Techboard
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.